NEJM:细胞减灭术后化疗可显著改善复发性卵巢癌患者预后

2021-12-02 MedSci原创 MedSci原创

对于复发性卵巢癌患者,相比于单纯化疗,细胞减灭术后化疗可显著延长患者总生存期

卵巢癌患者的主要治疗方法是手术切除,随后进行卡铂和紫杉醇联合化疗。新近的研究发现,额外进行贝伐单抗或PARP抑制剂全身治疗可改善患者无进展生存。目前复发性卵巢癌的标准治疗手段为全身治疗,但仅有少数证据表明全身治疗对复发性卵巢癌患者总生存期有益。近日研究人员评估了二次肿瘤细胞减灭术对复发性卵巢癌患者的临床意义。

复发性卵巢癌患者参与研究,患者接受不含铂类化疗至少6个月后首次复发,随机接受二次细胞减灭术(手术组)或对照(单纯铂化疗),随后接受铂类化疗。患者的AGO评分阳性,ECOG评分为0,腹水少于500mL,并且在首次手术时可见病灶完全切除。研究的主要终点是总生存率,同时评估了生存质量和预后因素。

407名患者参与研究,其中206名患者接受细胞减灭术联合化疗,201名患者接受单纯化疗。手术组75.5%的患者实现了完全切除。手术组的中位总生存期为53.7个月,非手术组为46.0个月(死亡风险比为0.75)。实现完全切除患者的预后最好,中位总生存期为61.9个月。所有亚组分析中手术均更具优势。两组随访1年后的生活质量指标无显著差异,未发生术后30天内围手术期死亡事件。

手术组在无进展生存期及总生存期方面均更具优势

研究认为,对于复发性卵巢癌患者,相比于单纯化疗,细胞减灭术后化疗可显著延长患者总生存期

原始出处:

Philipp Harter et al. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. N Engl J Med,December 2,2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1909938, encodeId=baaf19099388b, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Sep 15 06:38:47 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976053, encodeId=ec0d19e605323, content=<a href='/topic/show?id=e796610430e' target=_blank style='color:#2F92EE;'>#术后化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61043, encryptionId=e796610430e, topicName=术后化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Tue Nov 08 04:38:47 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692250, encodeId=d84a169225006, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Jan 18 05:38:47 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349636, encodeId=adf9134963602, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Dec 04 09:38:47 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076445, encodeId=09ba10e644500, content=春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Dec 03 07:21:30 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076320, encodeId=a90810e632024, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55ed6145165, createdName=ms8000002131364081, createdTime=Thu Dec 02 20:15:04 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1909938, encodeId=baaf19099388b, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Sep 15 06:38:47 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976053, encodeId=ec0d19e605323, content=<a href='/topic/show?id=e796610430e' target=_blank style='color:#2F92EE;'>#术后化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61043, encryptionId=e796610430e, topicName=术后化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Tue Nov 08 04:38:47 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692250, encodeId=d84a169225006, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Jan 18 05:38:47 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349636, encodeId=adf9134963602, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Dec 04 09:38:47 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076445, encodeId=09ba10e644500, content=春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Dec 03 07:21:30 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076320, encodeId=a90810e632024, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55ed6145165, createdName=ms8000002131364081, createdTime=Thu Dec 02 20:15:04 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1909938, encodeId=baaf19099388b, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Sep 15 06:38:47 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976053, encodeId=ec0d19e605323, content=<a href='/topic/show?id=e796610430e' target=_blank style='color:#2F92EE;'>#术后化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61043, encryptionId=e796610430e, topicName=术后化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Tue Nov 08 04:38:47 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692250, encodeId=d84a169225006, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Jan 18 05:38:47 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349636, encodeId=adf9134963602, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Dec 04 09:38:47 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076445, encodeId=09ba10e644500, content=春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Dec 03 07:21:30 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076320, encodeId=a90810e632024, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55ed6145165, createdName=ms8000002131364081, createdTime=Thu Dec 02 20:15:04 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1909938, encodeId=baaf19099388b, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Sep 15 06:38:47 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976053, encodeId=ec0d19e605323, content=<a href='/topic/show?id=e796610430e' target=_blank style='color:#2F92EE;'>#术后化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61043, encryptionId=e796610430e, topicName=术后化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Tue Nov 08 04:38:47 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692250, encodeId=d84a169225006, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Jan 18 05:38:47 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349636, encodeId=adf9134963602, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Dec 04 09:38:47 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076445, encodeId=09ba10e644500, content=春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Dec 03 07:21:30 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076320, encodeId=a90810e632024, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55ed6145165, createdName=ms8000002131364081, createdTime=Thu Dec 02 20:15:04 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1909938, encodeId=baaf19099388b, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Sep 15 06:38:47 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976053, encodeId=ec0d19e605323, content=<a href='/topic/show?id=e796610430e' target=_blank style='color:#2F92EE;'>#术后化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61043, encryptionId=e796610430e, topicName=术后化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Tue Nov 08 04:38:47 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692250, encodeId=d84a169225006, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Jan 18 05:38:47 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349636, encodeId=adf9134963602, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Dec 04 09:38:47 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076445, encodeId=09ba10e644500, content=春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Dec 03 07:21:30 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076320, encodeId=a90810e632024, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55ed6145165, createdName=ms8000002131364081, createdTime=Thu Dec 02 20:15:04 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2021-12-03 查查佳佳

    春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1909938, encodeId=baaf19099388b, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Sep 15 06:38:47 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976053, encodeId=ec0d19e605323, content=<a href='/topic/show?id=e796610430e' target=_blank style='color:#2F92EE;'>#术后化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61043, encryptionId=e796610430e, topicName=术后化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Tue Nov 08 04:38:47 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692250, encodeId=d84a169225006, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Jan 18 05:38:47 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349636, encodeId=adf9134963602, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Dec 04 09:38:47 CST 2021, time=2021-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076445, encodeId=09ba10e644500, content=春新碱和泼尼松 (CHOP) 联合疗法被广泛用作 PTCL 的一线治疗;但是,该方案的疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Fri Dec 03 07:21:30 CST 2021, time=2021-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076320, encodeId=a90810e632024, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55ed6145165, createdName=ms8000002131364081, createdTime=Thu Dec 02 20:15:04 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2021-12-02 ms8000002131364081

    学到了

    0

相关资讯

JAMA Oncol:BRCA1/2 基因突变携带者预防性输卵管切除术,术后生活质量仍然良好

荷兰研究者Steenbeek 等报告的一项非随机对照试验的结果表明,无论激素替代治疗如何,预防性输卵管切除术(RRS)后患者的绝经相关生活质量都优于降低险的输卵管卵巢切除术(RRSO)后的患者。一项国

Brit J Cancer:生命早期体重指数和乳腺癌、子宫内膜癌和卵巢癌风险的关系

对于生命早期肥胖,该研究的数据支持其与乳腺癌呈负相关,但与卵巢癌和子宫内膜癌风险呈正相关。

Nat Commun:细胞外基质和适应性粘附动力学共同驱动卵巢癌的化疗抗性

肿瘤微环境(TME)中的细胞外基质(ECM)衍生的生化和生物力学因素对癌细胞的转移和治疗抗性至关重要。

J Exp Clin Canc Res:癌症免疫治疗新突破——CD112R/CD112轴

从与癌症诊断、预后、治疗的关系,带你认识癌症免疫治疗冉冉升起的明日之星——CD112R/CD112轴!

Lancet Oncol:SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后

奥拉帕利维持治疗2年,可将晚期卵巢癌患者的无进展生存期延长至四年半之久